Weight-Loss Pill Race in 2026: Lilly Leads Novo Nordisk
Novo Nordisk and Eli Lilly to launch oral GLP-1 drugs in 2026. Despite Novo's head start, analysts predict Lilly's market leadership in obesity and diabetes treatments will persist for years. Explore the details.